Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen
This study has been terminated.
( primary efficacy analysis at Week 24 failed to demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir' )
Study NCT00443729 Information provided by Merck
First Received: March 2, 2007 Last Updated: September 30, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infection
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
HIV Infections
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Comparator: raltegravir
Comparator: placebo
Comparator: lopinavir (+) ritonavir
Comparator: placebo (unspecified)
Additional drug interventions recognized in this trial
Lopinavir
Protease Inhibitors
Ritonavir
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
HIV Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Merck
Back to top of Main Content
